10/3/2019 8:05:15 AM
Spero Reports Positive Recommendation To Continue Phase 3 Trial Of SPR994
7/16/2019 8:14:45 AM
Spero Therapeutics Receives $5.9 Mln Award From DoD
6/13/2019 8:09:57 AM
Spero Announces $10 Mln Registered Direct Offering Of Common Stock
3/29/2019 8:12:04 AM
Spero Therapeutics Gets FDA Fast Track Designation For SPR994 For CUTI And Acute Pyelonephritis
2/4/2019 7:07:49 AM
Spero Therapeutics Announces FDA Acceptance Of IND Application For SPR994
11/5/2018 8:05:28 AM
Spero Announces Positive Results From SPR720 IND-Enabling Studies And Plans To Initiate A Phase 1 Trial
10/11/2018 8:03:58 AM
Spero Therapeutics Secures QIDP Designation From FDA For Development Of SPR206
7/16/2018 7:03:58 AM
Spero Therapeutics Secures Funding Of $15.7 Mln, With Potential For Up To Addl $28.5 Mln Over 5 Years, From BARDA
7/9/2018 4:12:32 PM
Spero Therapeutics Announces Proposed Offering Of Common Stock
7/9/2018 7:31:40 AM
Spero Therapeutics Announces Positive Interim Phase 1 SAD/MAD Results For SPR994
5/23/2018 8:07:03 AM
Spero Therapeutics Announces Positive Top-Line Data For Two Product Candidates From Its Potentiator Platform
4/12/2018 8:01:50 AM
Spero Therapeutics Appoints Ian Critchley As Head Of Clinical Microbiology
4/2/2018 4:23:13 PM
Spero Therapeutics Q4 Loss/share $1.59 Vs. Loss $25.68 Year Ago